Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real‐World Study in Patients With Nonvalvular Atrial Fibrillation
These findings suggest that the choice of DOAC after a bleeding event can affect treatment outcomes in patients with atrial fibrillation.
Authors
- Elisabeth Vodicka (ORCID: https://orcid.org/0000-0002-7370-0919)
- Puza P. Sharma
- Anandkumar Dubey
- C Gao
- Kishorekumar Mathivanan
- Anakha Vettumthara Unnikrishnan
- Jenny Jiang
- Gregory Y. H. Lip
- Dong Cheng
- Rupesh Subash
Institutions
- Medical University of Białystok (PL)
- University of Liverpool (GB)
- Bristol-Myers Squibb (Germany) (DE)
- The University of Queensland (AU)
- Pfizer (United States) (US)
- Ochsner Medical Center (US)
- Liverpool Heart and Chest Hospital (GB)
- Sigma Research (United States) (US)
- Liverpool John Moores University (GB)
- Aalborg University (DK)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1161/jaha.125.044113
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00